Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.51 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2020 / 01:45PM GMT
Release Date Price: $552.25 (-7.18%)
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

Sorry about that for everyone who is viewing -- who is in the Regeneron session. So my name is Evan Seigerman. I'm the senior biopharma analyst here at Crédit Suisse. And welcome to Day 1 of our Virtual Health Care Conference. I really wish we're all in Scottsdale together as that would be a lot more fun, and a little easier, given some technical difficulties this morning.

But it's my pleasure to have Marion McCourt and Justin Holko from Regeneron. I'm really excited to just have a fantastic conversation about everything that's happening at Regeneron from the COVID-19 antibody cocktail, EYLEA, Dupixent and the oncology franchise.

And before we jump into Q&A, I just want to pass it over to Justin for a quick disclaimer statement. And then Marion, I want to give you the floor for a quick introduction.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Sure. Thank you. Actually 2 disclaimer statements. The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot